NO964431L - Ikke-spleisende varianter av gp350/220 - Google Patents

Ikke-spleisende varianter av gp350/220

Info

Publication number
NO964431L
NO964431L NO964431A NO964431A NO964431L NO 964431 L NO964431 L NO 964431L NO 964431 A NO964431 A NO 964431A NO 964431 A NO964431 A NO 964431A NO 964431 L NO964431 L NO 964431L
Authority
NO
Norway
Prior art keywords
protein
splicing variants
sequences
vectors
proteins
Prior art date
Application number
NO964431A
Other languages
English (en)
Other versions
NO319382B1 (no
NO964431D0 (no
Inventor
Richard Spaete
Winthrop T Jackman
Original Assignee
Aviron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aviron Inc filed Critical Aviron Inc
Publication of NO964431D0 publication Critical patent/NO964431D0/no
Publication of NO964431L publication Critical patent/NO964431L/no
Publication of NO319382B1 publication Critical patent/NO319382B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Surgical Instruments (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO19964431A 1994-04-18 1996-10-18 Isolert DNA-fragment som koder for EBV gp350-proteinet eller en forkortet versjon av dette, samt vektor, vertcelle og farmasoytisk sammensetning inneholdende DNA-fragmentet eller proteinet og fremgangsmate for fremstilling og anvendelse av disse NO319382B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22929194A 1994-04-18 1994-04-18
PCT/US1995/004611 WO1995028488A1 (en) 1994-04-18 1995-04-13 NON-SPLICING VARIANTS OF gp350/220

Publications (3)

Publication Number Publication Date
NO964431D0 NO964431D0 (no) 1996-10-18
NO964431L true NO964431L (no) 1996-12-11
NO319382B1 NO319382B1 (no) 2005-07-25

Family

ID=22860582

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19964431A NO319382B1 (no) 1994-04-18 1996-10-18 Isolert DNA-fragment som koder for EBV gp350-proteinet eller en forkortet versjon av dette, samt vektor, vertcelle og farmasoytisk sammensetning inneholdende DNA-fragmentet eller proteinet og fremgangsmate for fremstilling og anvendelse av disse

Country Status (25)

Country Link
US (3) US6054130A (no)
EP (1) EP0769056B1 (no)
JP (4) JP3447743B2 (no)
KR (1) KR100380953B1 (no)
CN (2) CN100415895C (no)
AT (1) ATE210184T1 (no)
AU (1) AU707837B2 (no)
BR (1) BR9507473A (no)
CA (1) CA2187908C (no)
CZ (1) CZ292283B6 (no)
DE (1) DE69524415T2 (no)
DK (1) DK0769056T3 (no)
ES (1) ES2170144T3 (no)
FI (2) FI118224B (no)
HU (1) HU221647B1 (no)
LV (1) LV11803B (no)
MY (1) MY114769A (no)
NO (1) NO319382B1 (no)
PL (1) PL181881B1 (no)
PT (1) PT769056E (no)
RU (1) RU2178807C2 (no)
SK (1) SK283446B6 (no)
TW (1) TW496897B (no)
UA (1) UA47403C2 (no)
WO (1) WO1995028488A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692749B1 (en) * 1994-04-18 2004-02-17 Medimmune Vaccines, Inc. Non-splicing variants of gp350/220
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
AU2582897A (en) * 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
CA2331258C (en) * 1998-06-12 2011-09-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
US20100297612A1 (en) * 2009-05-22 2010-11-25 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, quantitation, isolation and sequencing of cytomegalovirus and epstein-barr virus
US10461635B1 (en) * 2018-05-15 2019-10-29 Analog Devices Global Unlimited Company Low VIN high efficiency chargepump

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0051079B1 (de) * 1980-11-03 1984-09-26 Deutsche ITT Industries GmbH Binäres MOS-Ripple-Carry-Parallel-Addier/Subtrahierwerk und dafür geeignete Addier/Subtrahierstufe
US4707358A (en) * 1984-01-30 1987-11-17 The University Of Chicago Vaccine against Epstein-Barr Virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
DE3583564D1 (de) * 1984-08-23 1991-08-29 Hans Joachim Wolf Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
EP0312164A1 (en) * 1987-10-16 1989-04-19 Merck & Co. Inc. Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
WO1993019092A1 (fr) * 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220

Also Published As

Publication number Publication date
NO319382B1 (no) 2005-07-25
US6054130A (en) 2000-04-25
AU707837B2 (en) 1999-07-22
EP0769056A1 (en) 1997-04-23
CZ292283B6 (cs) 2003-08-13
KR100380953B1 (ko) 2003-10-10
DE69524415T2 (de) 2002-08-01
ES2170144T3 (es) 2002-08-01
CZ305496A3 (en) 1997-10-15
CN1152940A (zh) 1997-06-25
FI964186A0 (fi) 1996-10-18
JP2003230396A (ja) 2003-08-19
NO964431D0 (no) 1996-10-18
FI118224B (fi) 2007-08-31
AU2383895A (en) 1995-11-10
HU9602894D0 (en) 1996-12-30
US5824508A (en) 1998-10-20
SK283446B6 (sk) 2003-07-01
DE69524415D1 (de) 2002-01-17
PL181881B1 (pl) 2001-09-28
JP2005333990A (ja) 2005-12-08
CN100415895C (zh) 2008-09-03
ATE210184T1 (de) 2001-12-15
CN1495262A (zh) 2004-05-12
PT769056E (pt) 2002-05-31
PL316941A1 (en) 1997-02-17
JP4317786B2 (ja) 2009-08-19
HUT75831A (en) 1997-05-28
EP0769056B1 (en) 2001-12-05
JP3447743B2 (ja) 2003-09-16
FI20075338A (fi) 2007-05-10
CA2187908C (en) 2002-09-17
CN1118573C (zh) 2003-08-20
LV11803A (lv) 1997-06-20
US6458364B1 (en) 2002-10-01
SK134396A3 (en) 1997-06-04
WO1995028488A1 (en) 1995-10-26
TW496897B (en) 2002-08-01
UA47403C2 (uk) 2002-07-15
JP2004290199A (ja) 2004-10-21
HU221647B1 (hu) 2002-12-28
DK0769056T3 (da) 2002-04-02
CA2187908A1 (en) 1995-10-26
BR9507473A (pt) 1997-09-23
EP0769056A4 (en) 1998-03-04
LV11803B (en) 1998-01-20
FI964186A (fi) 1996-12-17
RU2178807C2 (ru) 2002-01-27
MY114769A (en) 2003-01-31
JPH10501687A (ja) 1998-02-17

Similar Documents

Publication Publication Date Title
FI20075338A (fi) gb350/220:n ei silmukoivia muutoksia
CA2263889A1 (en) P-selectin ligand proteins
WO1989009787A3 (en) Osteogenic devices
AU2058888A (en) Variants of bovine pancreatic trypsin inhibitor produced by recombinant DNA technology, process, expression vector and recombinant host therefor and pharmaceutical use thereof
CA2161808A1 (en) Bmp-11 compositions
IL115199A (en) Composition comprising a polynucleic acid molecule in a liposome and method using said composition
HUT54213A (en) Process for the enzymatic removal of n-terminal sequence of proteins
EP0875567A3 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
AU8258591A (en) Human mk gene and protein sequence
PT1259536E (pt) Métodos de preparação de péptidos
HU895788D0 (en) Process for producing peptides and medical products containing them
WO1995030001A3 (en) Novel p-selectin ligand protein
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
AU3595489A (en) Amblyommin, a new active substance for anticoagulant therapy
AU4034095A (en) Cyclohexapeptides and their mixtures, a process for preparing them, and their use
CA2163805A1 (en) Novel activating factor of leukocytes
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
ATE224403T1 (de) Verwendung von kaseinfragmenten als wachstumerförderer
CA2247998A1 (en) Fragments of cr1 and their use
HUT37109A (en) Process for the phosphinoylation of amino gropus of amino-acids, peptides and esters thereof

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees